| Chemical Properties | Back Directory | [density ]
1.427±0.06 g/cm3(Predicted) | [storage temp. ]
4°C, away from moisture and light | [form ]
Solid | [pka]
8.97±0.23(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
MPT0E028 is an orally active and selective HDAC inhibitor with IC50s of 53.0 nM, 106.2 nM, 29.5 nM for HDAC1, HDAC2 and HDAC6, respectively[1]. MPT0E028 reduces the viability of B-cell lymphomas by inducing apoptosis and possesses potent direct Akt targeting ability and reduces Akt phosphorylation in B-cell lymphoma. MPT0E028 has good anticancer activity[2]. | [IC 50]
HDAC1: 53.0 nM (IC50); HDAC2: 106.2 nM (IC50); HDAC6: 29.5 nM (IC50); HDAC8: 2532.6 nM (IC50) | [storage]
4°C, away from moisture and light | [References]
[1] Huang HL, et al. Anticancer activity of MPT0E028, a novel potent histone deacetylase inhibitor, in human colorectal cancer HCT116 cells in vitro and in vivo. PLoS One. 2012;7(8):e43645. DOI:10.1371/journal.pone.0043645
[2] Huang HL, et al. Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphoma in vitro and in vivo. Oncotarget. 2015 Mar 10;6(7):4976-91. DOI:10.18632/oncotarget.3213 |
|
|